

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
22 January 2004 (22.01.2004)

PCT

(10) International Publication Number  
**WO 2004/007492 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 417/06**,  
497/04, 417/04, 277/26, 327/06, A61K 31/426, A61P  
35/00

**RICHTER, Wolfgang** [DE/DE]; Leharstrasse 35, 81243  
München (DE).

(21) International Application Number:  
PCT/EP2003/007664

(74) Agents: **BOETERS, Hans, D. et al.**; Boeters & Liek,  
Bereiteranger 15, 81541 München (DE).

(22) International Filing Date: 15 July 2003 (15.07.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,  
SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US,  
UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
102 32 094.2 15 July 2002 (15.07.2002) DE  
102 55 660.1 28 November 2002 (28.11.2002) DE

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicants (*for all designated States except US*): **MOR-  
PHOCHEM AKTIENGESELLSCHAFT FÜR KOM-  
BINATORISCHE CHEMIE** [DE/DE]; Gmunder Str.  
37-37a, 81379 München (DE). **GESELLSCHAFT FÜR  
BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF)**  
[DE/DE]; Mascheroder Weg 1, 38124 Braunschweig (DE).


Published:  
— with international search report

(72) Inventors; and  
(75) Inventors/Applicants (*for US only*): **HOEFLE, Gerhard**  
[DE/DE]; Alter Weg 12a, 38124 Braunschweig (DE).

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: NOVEL MACROCYCLES FOR THE TREATMENT OF CANCER

(57) Abstract: The present invention relates to new Macro-  
cycles of Formula (I), and their use for the treatment of cancer.




### Novel Macrocycles for the treatment of cancer

Epothilones (DE4138042) are polyketide natural products that inhibit cancer cells by a mechanism similar to paclitaxel, and also are effective against paclitaxel-resistant tumours. Several epothilone derivatives are currently undergoing clinical trials for the cure of several cancers (Nicolaou et al. Angew. Chem. Int. Ed. 1998, 37, 2014-2045; Flörsheimer et al. Expert Opin. Ther. Patents 2001, 11, 951-968).

The object of the present invention is to provide new epothilone-like compounds with improved pharmacological properties.

The present invention provides compounds of Formula (I):




wherein

A is a heteroalkyl-, heterocycloalkyl-, heteroalkylcycloalkyl-, heteroaryl- or heteroarylalkyl-group,

U is hydrogen, halogen, an alkyl, heteroalkyl-, heterocycloalkyl-, heteroalkylcycloalkyl-, heteroaryl- or heteroarylalkyl-group,

G-E is selected from the following groups,



or is part of an optionally substituted phenyl ring,

R<sup>1</sup> is a C<sub>1</sub>-C<sub>4</sub>-alkyl-, a C<sub>2</sub>-C<sub>4</sub>-alkenyl-, a C<sub>2</sub>-C<sub>4</sub>-alkinyl- or a C<sub>3</sub>-C<sub>4</sub>-cycloalkyl-group,

V-W is a group of formula CH<sub>2</sub>CH or CH=C,

X is oxygen or a group of the formula NR<sup>2</sup>, wherein R<sup>2</sup> is hydrogen, an alkyl-, alkenyl-, alkynyl-, heteroalkyl-, aryl-, heteroaryl-, cycloalkyl-, alkylcycloalkyl-, heteroalkylcycloalkyl-, heterocycloalkyl-, aralkyl- or heteroarylalkyl-group and

R<sup>3</sup> and R<sup>4</sup> independently from each other represent hydrogen, C<sub>1</sub>-C<sub>4</sub>-alkyl or together are part of a cycloalkyl group with 3 or 4 ring atoms,

or a pharmacologically acceptable salt, solvate, hydrate or formulation thereof.

It should be appreciated that certain compounds of Formula (I) may have tautomeric forms from which only one might be specifically mentioned or depicted in the following description, different geometrical isomers (which are usually denoted as cis/trans isomers or more generally as (E) and (Z) isomers) or different optical isomers as a result of one or more asymmetric or chiral carbon atoms (which are usually nomenclatured under the Cahn-Ingold-Prelog or R/S system). Further, some compounds may display polymorphism. All these tautomeric forms, geometrical or optical isomers (as well as racemates and diastereomers) and polymorphous forms are included in the invention.

The term alkyl refers to a saturated straight or branched chain alkyl group, containing from one or two to ten carbon atoms, preferably from one or two to six carbon atoms, e.g. 1 or 2 to 4 carbon atoms, for example methyl, ethyl, propyl, iso-propyl, butyl, iso-butyl, tert.-butyl, n-hexyl, 2,2-dimethylbutyl or n-octyl groups.

The terms alkenyl and alkynyl refer to at least partially unsaturated straight or branched chain alkyl groups, containing from two to ten carbon atoms, preferably from two to six carbon atoms, e.g. 2 to 4 carbon atoms, for example ethenyl (vinyl), propenyl, iso-propenyl, butenyl, isoprenyl or hexa-2-enyl; ethynyl, propynyl or butynyl groups. Preferably alkenyl groups have one or two and especially one double bond, and preferably alkynyl groups have one or two and especially one triple bond.

The terms alkyl, alkenyl and alkynyl moreover refer to groups, wherein one or more hydrogen atoms are replaced independently

of each other by halogen atoms such as fluorine or chlorine, for example trifluoromethyl or 1,1-dichloroethyl groups.

The term heteroalkyl refers to an alkyl, alkenyl or alkynyl group as defined herein where one or more and preferably 1, 2 or 3 carbon atoms are replaced independently of each other by an oxygen, nitrogen, phosphorous or sulphur atom, for example an alkoxy group containing from one to ten carbon atoms, preferably from one to six carbon atoms, e.g. 1 to 4 carbon atoms, such as methoxy, ethoxy, propoxy, iso-propoxy, butoxy or tert.-butoxy; a (1-4C)alkoxy(1-4C)alkyl group such as methoxymethyl, ethoxymethyl, 1-methoxyethyl, 1-ethoxyethyl, 2-methoxyethyl or 2-ethoxyethyl; or a cyano group; or a 2,3-dioxyethyl group.

The term heteroalkyl furthermore refers to a group derived from a carboxylic acid or carboxylic acid amide containing from one to ten carbon atoms, preferably from one to six carbon atoms, e.g. 1 to 4 carbon atoms, and may, for example, be acyl containing from one to ten carbon atoms, preferably from one to six carbon atoms, e.g. 1 to 4 carbon atoms, such as acetyl, propionyl, butyryl or pivaloyl; acyloxy containing from one to ten carbon atoms, preferably from one to six carbon atoms, e.g. 1 to 4 carbon atoms such as acetyloxy, propionyloxy, butyryloxy or pivaloyloxy; carboxyalkyl containing from one to ten carbon atoms, preferably from one to six carbon atoms, e.g. 1 to 4 carbon atoms such as carboxymethyl, carboxyethyl, carboxypropyl, carboxybutyl, carboxyalkyl ester containing from one to ten carbon atoms, preferably from one to six carbon atoms, e.g. 1 to 4 carbon atoms, such as carboxyalkyl methyl ester, carboxyalkyl ethyl ester, carboxyalkyl propyl ester, carboxyalkyl isopropyl ester, carboxyalkyl butyl ester or

carboxyalkyl tert.-butyl ester, carboxyalkyl amide or alkylcarbamoyl such as N-(1-4C)alkylcarbamoyl or N,N'-(1-4C)dialkylcarbamoyl) containing from one to ten carbon atoms, preferably from one to six carbon atoms, e.g. 1 to 4 carbon atoms such as N-methylcarbamoyl, N-ethylcarbamoyl, N-propylcarbamoyl, N,N'-dimethylcarbamoyl, N-ethyl-N-methylcarbamoyl or N,N'-dipropylcarbamoyl, alkoxy-carbonyl containing from one to ten carbon atoms, preferably from one to six carbon atoms, e.g. 1 to 4 carbon atoms, such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxy- or tert.-butoxycarbonyl or alkoxy-carbonyloxy containing from one to ten carbon atoms, preferably from one to six carbon atoms, e.g. 1 to 4 carbon atoms such as methoxycarbonyloxy, ethoxycarbonyloxy, propoxycarbonyloxy, isopropoxycarbonyloxy, butoxycarbonyloxy or tert.-butoxycarbonyloxy.

The term cycloalkyl refers to a saturated or partially unsaturated cyclic group, e. g. a cycloalkenyl group, having one or more and preferably one or two rings, containing from three to 14 ring carbon atoms, preferably from three, four, five or six to nine or ten carbon atoms, for example cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, tetralin, cyclopentenyl or cyclohex-2-enyl groups.

The term heterocycloalkyl refers to a cycloalkyl group as defined herein where one or more carbon atoms are replaced independently of each other by one or more oxygen, nitrogen, phosphorous or sulphur atoms. Specific examples for heterocyclalkyl are piperidino, morpholino, N-methyl-piperazino or N-phenyl-piperazino groups.

The term aryl or ar refers to an aromatic cyclic group, having one or more rings, containing from five to 14 ring carbon atoms, preferably from five or six to nine or ten ring carbon atoms, for example phenyl, inden or naphthyl groups. Specific examples are a benzyl, tolyl, phenethyl, biphenyl, xylyl, cumyl, 2-, 3- or 4-methoxyphenyl, 2-, 3- or 4-ethoxyphenyl, 4-carboxyphenyl alkyl or a 4-hydroxyphenyl group.

The term heteroaryl refers to an aryl group as defined herein where one, two or more carbon atoms are replaced independently of each other by an oxygen, nitrogen, phosphorous or sulphur atom, for example 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-imidazolyl, 3-pyrazolyl, quinolinyl, isoquinolinyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, oxadiazolyl, thiadiazolyl, indolyl, indazolyl, tetrazolyl, pyrazinyl, pyridinyl, pyrimidinyl and pyridazinyl groups.

The terms aralkyl and heteroarylalkyl refer to groups that comprise both aryl or, respectively, heteroaryl as well as alkyl, alkenyl, alkynyl and/or heteroalkyl (for example alkoxy groups in case of aralkyloxy) and/or cycloalkyl and/or heterocycloalkyl ring systems as defined herein. Examples are the tetrahydroisoquinolinyl, benzyl, benzyloxy, 2- or 3-ethyl-indolyl or 4-methylpyridino groups.

The terms alkylcycloalkyl and heteroalkylcycloalkyl refer to groups that comprise both cycloalkyl or, respectively, heterocycloalkyl as well as alkyl, alkenyl, alkynyl and/or heteroalkyl groups as defined herein.



Any alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, hetero-cycloalkyl, aryl, heteroaryl, aralkyl or heteroarylalkyl groups as defined herein may be substituted with one or more substituents selected from the group consisting of halogen atoms,  $\text{NH}_2$ ,  $\text{SH}$ ,  $\text{NO}_2$  and  $\text{OH}$  groups and unsubstituted alkyl, heteroalkyl, aryl, aralkyl, aralkyloxy, heteroaryl, cycloalkyl and heterocycloalkyl groups as defined herein.

The term "optionally substituted" refers to groups wherein one or more hydrogen atoms may be replaced independently of each other by a halogen atom, a  $\text{NH}_2$ ,  $\text{SH}$ ,  $\text{NO}_2$  or  $\text{OH}$  group or by a unsubstituted alkyl, heteroalkyl, aryl, aralkyl, aralkyloxy, heteroaryl, cycloalkyl or heterocycloalkyl group as defined herein.

Preferred and/or advantageous embodiments of the invention are subject-matter of the subclaims.

Preferred are compounds of formula (I), wherein A is a group of the formula  $-\text{C}(\text{CH}_3)=\text{CHR}^5$  or  $-\text{CH}=\text{CHR}^5$ , wherein  $\text{R}^5$  is a heteroaryl- or a heteroarylalkyl group, especially an optionally substituted 5- or 6-membered heteroaryl group.

Further preferred are compounds of formula (I), wherein A is a group of formula (II) or (III):





wherein Q is sulphur, oxygen or NR<sup>7</sup> (especially oxygen or sulphur), wherein R<sup>7</sup> is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl or C<sub>1</sub>-C<sub>4</sub> heteroalkyl, z is Nitrogen or CH (especially CH) and R<sup>6</sup> is OR<sup>8</sup>, NHR<sup>8</sup>, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkenyl, C<sub>1</sub>-C<sub>4</sub> alkynyl or C<sub>1</sub>-C<sub>6</sub> heteroalkyl (especially methyl, CH<sub>2</sub>OR<sup>8</sup> or CH<sub>2</sub>NHR<sup>8</sup>), wherein R<sup>8</sup> is hydrogen, C<sub>1</sub>-C<sub>4</sub> alkyl or C<sub>1</sub>-C<sub>4</sub> heteroalkyl (especially hydrogen).

Moreover preferred are compounds of formula (I), wherein R<sup>2</sup> is hydrogen or C<sub>1</sub>-C<sub>4</sub> alkyl.

Further preferred are compounds of formula (I), wherein X is oxygen or NH.

Moreover preferred are compounds of formula (I), wherein R<sup>1</sup> is methyl or ethyl (especially methyl).

Further preferred are compounds of formula (I), wherein R<sup>3</sup> and R<sup>4</sup> are methyl groups.

Moreover preferred are compounds of formula (I), wherein U is hydrogen, fluorine, methyl, trifluoromethyl or COOH (especially hydrogen).

Further preferred are compounds of formula (I), wherein G-E is selected from the following groups:



Moreover preferred are compounds of formula (I), wherein V-W is CH<sub>2</sub>CH.

Further preferred are compounds of formula (I), wherein the absolute stereochemistry is the same as in the natural occurring epothilones B and/or D.

The present invention also relates to pharmacologically acceptable salts, or solvates and hydrates, respectively, and to compositions and formulations of compounds of Formula (I). The pharmaceutical compositions according to the present invention contain at least one compound of Formula (I) as the active agent and optionally carriers and/or diluents and/or adjuvants.

Examples of pharmacologically acceptable salts of sufficiently basic compounds of Formula (I) are salts of physiologically acceptable mineral acids like hydrochloric, hydrobromic, sulfuric and phosphoric acid; or salts of organic acids like methanesulfonic, p-toluenesulfonic, lactic, acetic, trifluoroacetic, citric, succinic, fumaric, maleinic and salicylic acid. Further, a sufficiently acid compound of Formula (I) may form alkali or earth alkaline metal salts, for example sodium, potassium, lithium, calcium or magnesium salts; ammonium salts; or organic base salts, for example methylamine, dimethylamine, trimethylamine, triethylamine, ethylenediamine, ethanolamine, choline hydroxide, N-methyl-D-aminomethane (meglumin), piperidine, morpholine, tris-(2-hydroxyethyl)amine, lysine or arginine salts. Compounds of Formula (I) may be solvated, especially hydrated. The hydratisation can occur during the process of production or as a consequence of the hygroscopic nature of the initially water free compounds of Formula (I). The compounds of Formula (I) contain asymmetric C-atoms and may be present either as achiral compounds, mixtures of dia-

stereomers, mixtures of enantiomers or as optically pure compounds.

The present invention also relates to pro-drugs (cf. for example R. B. Silverman, Medizinische Chemie, VCH Weinheim, 1995, Kapitel 8, S. 361ff) which are composed of a compound of Formula (I) and at least one pharmacologically acceptable protective group which will be cleaved off under physiological conditions, such as an alkoxy-, aralkyloxy-, acyl- or acyloxy group as defined herein, e.g. ethoxy, benzyloxy, acetyl or acetyloxy.

As mentioned above, therapeutically useful agents that contain compounds of Formula (I), their solvates, salts and formulations are also comprised in the scope of the present invention. Furthermore the use of compounds of formula (I) for the manufacture of medicaments for the treatment of cancer is also comprised in the scope of the present invention. In general, compounds of Formula (I) will be administered by using the known and acceptable modes known in the art, either alone or in combination with any other therapeutic agent. Such therapeutically useful agents can be administered by one of the following routes: oral, e.g. as tablets, dragees, coated tablets, pills, semisolids, soft or hard capsules, for example soft and hard gelatine capsules, aqueous or oily solutions, emulsions, suspensions or syrups, parenteral including intravenous, intramuscular and subcutaneous injection, e.g. as an injectable solution or suspension, rectal as suppositories, by inhalation or insufflation, e.g. as a powder formulation, as microcrystals or as a spray (e.g. liquid aerosol), transdermal, for example via a transdermal delivery system (TDS) such as a plaster containing the active ingredient or intranasal. For the


production of such tablets, pills, semisolids, coated tablets, dragees and hard, e.g. gelatine, capsules the therapeutically useful product may be mixed with pharmaceutically inert, inorganic or organic excipients as are e.g. lactose, sucrose, glucose, gelatin, malt, silica gel, starch or derivatives thereof, talc, stearinic acid or their salts, dried skim milk, and the like. For the production of soft capsules one may use excipients as are e.g. vegetable, petroleum, animal or synthetic oils, wax, fat, polyols. For the production of liquid solutions, emulsions or suspensions or syrups one may use excipients as are e.g. water, alcohols, aqueous saline, aqueous dextrose, polyols, glycerin, vegetable, petroleum, animal or synthetic oils. For suppositories one may use excipients as are e.g. vegetable, petroleum, animal or synthetic oils, wax, fat and polyols. For aerosol formulations one may use compressed gases suitable for this purpose, as are e.g. oxygen, nitrogen and carbon dioxide. The pharmaceutically useful agents may also contain additives for conservation, stabilisation, e.g. UV stabilizers, emulsifiers, sweetener, aromatisers, salts to change the osmotic pressure, buffers, coating additives and antioxidants.

Combinations with other therapeutic agents may include other therapeutically useful agents, e.g. that are used to prevent or treat cancer.

For the prevention and/or treatment of cancer the dose of the biologically active compound may vary within broad limits and can be adjusted to the individual needs. In general a dose of 0.1 microgram to 100 milligram per kilogram body weight per day is appropriate, with a preferred dose of 10 micrograms to 25

milligram/kilogram per day. In appropriate cases the dose may be also higher or lower than given above.


Compounds (IVa), (IVb), (Va) and (Vb) are key building blocks in the synthesis of compounds according to the present invention and are also included in the scope of the invention.



Herein, the groups PG independently from each other represent hydrogen or protecting groups for alcohols and/or acids (P. J. Kocienski, Protecting Groups, Georg Thieme Verlag, Stuttgart, 1994; T. W. Greene, P. G. M. Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, New York, 1999). Examples are silyl groups such as TBDMS, Acyl groups such as Acetyl or p-Methoxybenzyl groups or esterifying groups.


In the following the invention is described in more detail with reference to examples. These examples are intended for illustration only and are not to be construed as any limitation.

## Examples




(3S)-3-(tert-Butyl-dimethyl-silanyloxy)-tetrahydrofuranone

reproduced from *Chem. Eur. J.* 1999, 5, 2492, starting from commercially available (3S)-3-Hydroxytetrahydrofuran-2-one.



(3S)-3-(tert-Butyl-dimethyl-silanyloxy)-2-methyl-tetrahydrofuran-2-ol

reproduced from *Chem. Eur. J.* 1999, 5, 2492.




(3*S*)-3,5-Di-(*tert*-butyl-dimethyl-silanyloxy)-pentan-2-one

reproduced from *Chem. Eur. J.* 1999, 5, 2492.




4-(Chloromethyl)-2-methyl-1,3-thiazole

reproduced from *J.Org.Chem.* 2000, 65, 7456.




Diethyl (2-methylthiazol-4-yl)methanephosphonate

reproduced from *Chem. Eur. J.* 1996, 2, 1477.



(3*S*,4*E*)-1,3-Di-(*tert*-butyl-dimethyl-silanyloxy)-4-methyl-5-(2-methyl-1,3-thiazol-4-yl)-4-pentene


reproduced from *Chem. Eur. J.* 1996, 2, 1477.



(3*S*,4*E*)-3-(*tert*-Butyl-dimethyl-silanyloxy)-4-methyl-5-(2-methyl-1,3-thiazol-4-yl)-4-penten-1-ol


reproduced from *Chem. Eur. J.* 1996, 2, 1477.






(3*S*,4*E*)-3-(*tert*-Butyl-dimethyl-silanyloxy)-4-methyl-5-(2-methyl-1,3-thiazol-4-yl)-4-pentenal

reproduced from *J.Org.Chem.* 2000, 65, 7456.




bis-Trifluoroethyl ethylphosphonate

reproduced from *Synth.Comm.* 1991, 21, 2391



bis-Trifluoroethyl 2-ethoxy-2-oxo-1-methyl-ethylphosphonate


reproduced from *Synth.Comm.* 1991, 21, 2391



**Ethyl (2Z,5S,6E)-5-(tert-Butyl-dimethyl-silanyloxy)-2,6-dimethyl-7-(2-methyl-1,3-thiazol-4-yl)-hepta-2,6-dienoate**

To a cooled ( $-78^{\circ}\text{C}$ ) solution of phosphonoacetate (5.12 g, 14.8 mmol) and 18-crown-6 (9.05 g) in tetrahydrofuran (142 mL) was added a solution of potassium bis(trimethylsilyl)amide (26.6 mL, 0.5M in toluene, 13.3 mmol) at. The cooling bath was removed and the reaction was stirred 15 minutes. After cooling again to  $-78^{\circ}\text{C}$ , a solution of aldehyde (3.79 g crude, 11.7 mmol) in tetrahydrofuran (57 mL) was added drop wise over 60 minutes. The mixture was stirred one hour at this temperature. After warming, 10%  $\text{NaHSO}_4$  (100 mL) was added. The two phases were separated and the aqueous layer was extracted with ethyl acetate (3 x 100 mL). The combined organic layers were washed with brine and concentrated in vacuo. The residue was chromatographed (ethyl acetate-hexane 1:19) to afford the title ester (3.65 g, 8.9 mmol).


$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz): 6.93 (s, 1H); 6.52 (s, 1H); 5.98 (td,  $J = 1.5, 7.3\text{ Hz}$ , 1H); 4.21 (t,  $J = 5.5\text{ Hz}$ , 1H); 2.75 (m, 2H); 2.73 (s, 3H); 2.0 (s, 3H); 1.88 (s, 3H); 0.9 (s, 9H); 0.06 (s, 3H); 0.02 (s, 3H).



(2Z,5S,6E)-5-(*tert*-Butyl-dimethyl-silanyloxy)-2,6-dimethyl-7-(2-methyl-1,3-thiazol-4-yl)-hepta-2,6-dien-1-ol

To a solution of ester (3.65g, 8.9mmol) in tetrahydrofuran (168 mL) was added drop wise diisobutyl aluminium hydride (27mL) at 0°C. The reaction mixture was then stirred at the same temperature for 90 minutes. The reaction was quenched by adding methanol (2mL), diluted with ether (135 mL) and saturated K-Na tartrate (135mL). The mixture was stirred at room temperature for 45 minutes. The two phases were separated and the aqueous layer was extracted with ether (3 x 150mL). The combined ethereal layers were washed with brine and dried over sodium sulfate. The organic phase was filtered over a small pad of silica gel. The filtrate was concentrated in vacuo to afford the title alcohol (2.99g, 8.1mmol) as an oil.

<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): 6.94 (s, 1H); 6.46 (s, 1H); 5.32 (td, J= 2.5, 8.0Hz, 1H); 4.13 (d, J= 12Hz, 1H); 4.11 (m, 1H); 4.01 (d, J= 12Hz, 1H); 2.72 (s, 3H); 2.46 (td, J= 8.0, 14.1Hz), 2.22 (m, 1H); 2.03 (d, J= 1Hz, 3H); 1.81 (s, 3H); 0.90 (s, 9H); 0.07 (s, 3H); 0.05 (s, 3H).




(3S)-4-[7-Bromo-3-(tert-butyl-dimethyl-silanyloxy)-2,6-dimethyl-hepta-1,5-dienyl]-2-methyl-thiazole

reproduced from *J.Am.Chem.Soc.* 2001, 123, 5407.

To a solution of alcohol (1g, 2.72mmol) in dichloromethane (9mL) were added at 0°C, triethylamine (0.581mL, 4.16 mmol) and methanesulfonic anhydride (0.629g, 3.6mmol). After 10 minutes, acetone (9mL) was added followed by lithium bromide (1.44g, 16.73 mmol). The mixture was then stirred at room temperature for 40 minutes. The reaction mixture was diluted with dichloromethane and was filtered through hydromatrix (10% NaHSO<sub>4</sub>) and eluted with dichloromethane. The filtrate was concentrated *in vacuo* and the residue was columned (ethyl acetate-hexane 1:9) to afford the title bromide (0.868g, 2mmol).

<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): 6.95 (s, 1H); 6.50 (s, 1H); 5.43 (td, J= 1.6, 7.3Hz, 1H); 4.16 (dd, J= 5.4, 7.6Hz, 1H); 4.06 (d, J= 9.6Hz, 1H); 3.90 (d, J= 9.6Hz, 1H); 2.73 (s, 3H); 2.39-2.33 (m, 2H); 2.03 (d, J= 1Hz, 3H); 1.84 (s, 3H); 0.9 (s, 9H); 0.06 (s, 3H); 0.02 (s, 3H).




[(6*S*)-6-(*tert*-Butyl-dimethyl-silanyloxy)-3,7-dimethyl-8-(2-methyl-1,3--thiazol-4-yl)-octa-3,7-dienyl]-triphenyl-phosphonium bromide

reproduced from *J.Am.Chem.Soc.* 2001, 123, 5407.

To a solution of methyltriphenylphosphonium (3.16g, 8.84mmol) in tetrahydrofuran (30mL) cooled to  $-78^{\circ}\text{C}$ , was added *n*-butyllithium (3.8mL, 2.3N in hexanes, 8.74 mmol). The reaction mixture was stirred for one hour at the same temperature and a pre-cooled ( $-78^{\circ}\text{C}$ ) solution of bromide (0.868g, 2mmol) in tetrahydrofuran (13mL + 6mL rinse) was introduced drop wise via a canula in the mixture. The reaction was then stirred one hour at this temperature and methanol (7mL) was added. After evaporation to dryness, the residue was chromatographed (dichloromethane-methanol 19:1). The fractions containing the desired product were pooled and washed twice with water (2 x 150mL). The organic layer was then dried over sodium sulfate and dried under reduced pressure to afford the title phosphonium (1.037g, 1.47mmol) as a foam.

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz): 7.9-7.6 (m, 15H); 6.89 (s, 1H), 6.37 (s, 1H); 5.22 (m, 1H); 3.98 (m, 1H); 3.8-3.6 (m, 2H); 2.72 (s, 3H); 2.4-2.2 (m, 2H); 1.92 (s, 3H); 1.87 (s, 3H); 9.82 (s, 9H); -0.07 (s, 3H); -0.09 (s, 3H).


For the synthesis of the epoxides of the thioepothilone derivatives of the present invention, the epoxide of the above product can be synthesized according to standard procedures and then be used for the further synthesis.




**2,2,2-Trichloro-acetimidic acid 4-methoxy-benzyl ester**

adapted from *Tetrahedron Letters*, 1996, 37, 1461


To a solution of 4-methoxy benzyl alcohol (17g, 123mmol) in dichloromethane (170mL) was added 50% aqueous potassium hydroxyde solution (170mL) and tetrabutylammonium hydrogensulfate (NBu<sub>4</sub>HSO<sub>4</sub>) (0.257 g). After cooling to -10C, trichloroacetonitrile (14.9mL, 148mmol) was added drop wise. The mixture was then stirred 30 minutes at the same temperature and then 30 minutes at room temperature. The two phases were separated and the aqueous layer was extracted twice with dichloromethane (2 x 170mL). The combined organic layers were washed with brine and dried over sodium sulfate. The solvent was then removed under reduced pressure. The resulting oil was used in the next step without further purification.



(2S)-3-(4-Methoxy-benzyloxy)-2-methyl-propionic acid methyl ester

reproduced from *J. Am. Chem. Soc.*, 2000, 122, 8654

(2R)-3-(4-Methoxy-benzyloxy)-2-methyl-propan-1-ol

reproduced from *J.Am.Chem.Soc*, 2000, 122, 8654

(2S)-3-(4-Methoxy-benzyloxy)-2-methyl-propanal


reproduced from *J.Am.Chem.Soc*, 2000, 122, 8654

**5-Ethylsulfonyl-1-phenyl-1H-tetrazole**

modified procedure taken from *J.Chem.Soc, Perkin Trans 1*, 1999, 955-968

To a solution of 1-Phenyl-5-mercaptotetrazole (25g, 140mmol) in ethanol (250mL) was added powdered potassium hydroxide (9.5g). The resulting mixture was refluxed for 1h, and ethyl iodide (12mL, 150mmol) was added drop wise. The reaction proceeded under reflux for 18 h. After cooling, the volatiles were removed under reduced pressure and the residue was partitioned between water (300mL) and ether (300mL). The organic layer was washed with sat. NaHCO<sub>3</sub> (2 x 120mL) and brine (100mL). After concentration *in vacuo*, the residue (28.71g) was taken up in methanol (250mL) and water (250mL). After cooling to 0C, Oxone (400g) was added portion wise. The mixture was then stirred for 1 h at room temperature before refluxing for 18h. After cooling, ether (300mL) was added and the solids were removed by filtration. The filtrate was then concentrated in *vacuo*, and the white solid was filtered. The latter was thoroughly washed with water and dried under reduced pressure over night to yield 5-Ethylsulfonyl-1-phenyl-1H-tetrazole (27.7g, 116mmol) as a white solid.






**(2S, 3E)-1-(4-Methoxybenzyloxy)-2-methyl-pent-3-ene**

adapted from *J.Chem.Soc, Perkin Trans 1*, 1999, 955-968

To a stirred solution of the aldehyde (47.55mmol) and 5-Ethylsulfonyl-1-phenyl-1H-tetrazole (13.61g, 57.12mmol) in 1,2-dimethoxyethane (305mL), cooled to -60C, was added drop wise a solution of potassium bis(trimethylsilyl)amide (145mL, 0.5M in toluene, 72.5mmol) over 1 h (keeping the internal temperature between -60 and -70C). The reaction was then stirred for further 30 minutes. Water (36mL) was then added and the reaction was allowed to warm up. The two phases were separated and the aqueous layer was extracted with ethyl acetate (3 x 100mL). The combined organic layers were washed with brine and dried over magnesium sulfate. After evaporation to dryness, the residue was then chromatographed (ethyl acetate-hexane 1-19) to afford the title alkene as a 93-7 mixture (9.71g, 44mmol) as an oil.

<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): 7.27 (m, 2H); 6.88 (m, 2H); 5.44 (m, 2H); 4.47 (s, 2H); 3.33 (dd, J= 6.6, 9.3Hz, 1H); 3.24 (dd, J= 7.2, 9.3Hz, 1H); 2.44 (app p, J= 6.9Hz, 1H); 1.67 (dd, J= 1.2, 6.0Hz, 3H); 1.01 (d, J= 6.6Hz, 3H):

<sup>13</sup>C NMR (75MHz, CDCl<sub>3</sub>): 159, 133.9, 130.7, 129.1 (2C), 124.5, 113.6 (2C); 75.2, 72.6, 55.2, 36.8, 18.0, 17.3.




(2S, 3S, 4R)-5-(4-Methoxy-benzyloxy)-4-methyl-pentan-2,3-diol

To a vigorously stirred mixture of 2-methyl-2-propanol (140mL) and water (165mL) were added AD mix alpha or beta, respectively (58g) and methanesulfonamide (4.17g, 43.8mmol). The resulting clear solution was then cooled down to 0°C, and a solution of alkene (9.67g, 44mmol) in 2-methyl-2-propanol (20mL + 7mL rinse) was added. The mixture was further stirred at 0°C for 18 h. Sodium pyrobisulfite (60g) was added portion wise. The resulting clear phases were separated and the aqueous layer was extracted twice with ethyl acetate (2 x 200mL). The combined organic layers were washed with brine, dried over sodium sulfate and then concentrated in vacuo. The residue was purified over silica gel (ethyl acetate-hexane 2-1) to afford the title diol (9.11g, 35.5mmol) as an oil.

MS (ESI, m/z) :277.3 [M+Na]

<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): 7.26 (m, 2H); 6.89 (m, 2H); 4.44 (dd, AB; J= 11.9, 12.6Hz, 2H); 3.81 (s, 3H); 3.79 (m overlapped, 1H); 3.55 (dd, J= 3.9, 9.3Hz, 1H); 3.42 (m, 2H); 2.50 (br s, 2H); 1.90 (m, 1H); 1.16 (d, J= 6.4Hz, 3H); 0.96 (d, J= 7.14Hz, 3H).

<sup>13</sup>C NMR (75MHz, CDCl<sub>3</sub>): 159.2, 129.8, 129.2 (2C), 113.7 (2C), 79.4, 73.3, 72.9, 67.8, 55.2, 35.7, 19.0, 11.8.




(2*S*,3*S*,4*R*)-5-(4-Methoxy-benzyloxy)-4-methyl-2,3-epoxy-pentane

adapted from *Tetrahedron*, 1992, 48, 10515.

Trimethyl orthoacetate (5.2mL, 40.85mmol) was added to a solution of the corresponding diol (8.9g, 35mmol) in dichloromethane (110mL) containing 4-toluene sulfonic acid (0.111g, 0.583mmol). The reaction was then stirred at room temperature for 15 minutes. The volatiles were removed under reduced pressure and the residue was further dried under high vacuum for 10 minutes. The residue was taken up in dichloromethane (110mL) and methanol (0.1mL) and trimethylchlorosilane (6.2mL, 49mmol) was added. The reaction was then stirred for 6 h at room temperature. The volatiles were removed under reduced pressure and the residue was taken up in methanol (120mL) and potassium carbonate (10g) was added. The mixture was then stirred for 1 h. The volatiles were removed under reduced pressure and the residue was partitioned between water (150mL) and ethyl acetate (200mL). The aqueous layer was extracted once more with ethyl acetate (200mL). The combined organic layers were washed with brine (50mL), dried over sodium sulfate and evaporated to dryness. The residue was purified by chromatography (ethyl acetate-hexane 1-6) to afford the title epoxide (5.0g, 21.15mmol) as an oil.

$^1\text{H}$  NMR (300MHz,  $\text{CDCl}_3$ ): 7.27 (m, 2H); 6.89 (m, 2H); 4.44 (s, 2H); 3.81 (s, 3H); 3.40 (m, AB, 2H); 2.87 (dq,  $J=2.3, 5.2\text{Hz}$ , 1H); 2.57 (dd,  $J=2.3, 6.81\text{Hz}$ , 1H); 1.72 (app hept,  $J=6.8\text{Hz}$ , 1H), 1.29 (d,  $J=5.2\text{Hz}$ , 3H); 0.99 (d,  $J=6.8\text{Hz}$ , 3H).



### 2-Benzylsulfanyl-2-methyl-propionaldehyde

Sulfuryl chloride (13.2mL, 162mmol) was added drop wise to a solution of benzyl mercaptan (19.2mL, 162mmol) and pyridine (13.2mL, 164mmol) in dichloromethane (810mL) at  $-78^\circ\text{C}$ . The reaction mixture was stirred for 15 minutes whereupon a precipitate formed. The reaction mixture was warmed to  $0^\circ\text{C}$  for 30 min. and a clear solution evolved. After cooling  $-78^\circ\text{C}$ , a solution of 2-methyl-trimethylsilyloxypropene (30mL, 163.2mmol) in tetrahydrofuran (810mL) was added slowly over 1 h. The reaction mixture was further stirred at  $-78^\circ\text{C}$  for 1h, then warmed to  $0^\circ\text{C}$ , and stirred for 30 minutes. The solvent was removed under reduced pressure. The residue was taken up in ether (200mL) and the resulting solution was filtered over a small pad of silica gel. The solvent was then removed to afford crude aldehyde (31.2g) as an oil. The title aldehyde was then carried on without further purification.


$^1\text{H}$  NMR (300MHz,  $\text{CDCl}_3$ ): 9.13 (s, 1H); 7.26 (m, 5H); 3.51 (s, 2H); 1.39 (s, 6H).



### 2-(1-Benzylsulfanyl-1-methyl-ethyl)-[1,3]dioxolane

A solution of crude aldehyde (31.2 g, 160.6mmol) and ethylene glycol (20g, 322mmol) in toluene (300mL) containing *p*-TsOH (1.5g, 7.8mmol) was refluxed for 4h using a Dean-Stark trap to remove the water formed. After cooling, triethylamine (3mL, 21mmol) was added. The volatiles were removed under reduced pressure and the residue was chromatographed (hexane-ethyl acetate 49-1 then 9-1) to afford the title ketal (32.4g, 136mmol) as an oil.

$^1\text{H}$  NMR (300MHz,  $\text{CDCl}_3$ ): 7.29 (m, 5H); 4.86 (s, 1H); 3.96 (m, 4H); 3.94 (s, 2H); 1.31 (s, 6H).




### 2-[1,3]Dioxolan-2-yl-propane-2-thiol

Finely divided sodium metal (8.08g, 351mmol) was added portion wise to condensed ammonia (800mL) whereupon a intense blue color appeared. A solution of ketal (32.4g, 136mmol) in tetrahydrofuran (212mL) was added drop wise. After 20 minutes, the reaction mixture was quenched with ethanol (70mL) until the blue color disappeared. Ether (300mL) was added to the mixture

which was allowed to warm up at room temperature. After NH<sub>3</sub> was completely evaporated, the reaction mixture was washed with sat NH<sub>4</sub>Cl (100mL) and brine (100mL). The organic phase was dried over magnesium sulfate and then filtered over a pad of silica gel. The filtrate was concentrated to dryness to afford the title compound contaminated with dihydrostilbene. The material was further dried for 10 minutes under high vacuum to afford the title thiol (18.36g)

<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): 4.85 (s, 1H); 4.00 (s, 1H); 3.94 (m, 4H); 1.30 (s, 6H).




(2R,3S,4R)-4-(1-[1,3]Dioxolan-2-yl-1-methyl-ethyl-sulfanyl)-1-(4-methoxy-benzyloxy)-2-methyl-pentan-3-ol

To a suspension of sodium hydride (3 eq., 60% in dispersion, unwashed) in N,N-dimethylformamide (4 mL/mmol) was added crude thiol (3 eq.) at 0°C. The mixture was stirred at room temperature for 30 minutes, and a solution of the epoxide (1 eq.) in N,N-dimethylformamide was then added. The reaction mixture was heated at 80°C (temperature in the flask !) for at least 17 h. Water (95mL) was added and the mixture was concentrated to dryness under high vacuum. The residue was partitioned between water (200mL) and ethyl acetate (200mL). The aqueous layer was extracted three times with ethyl acetate

(3 x 200mL). The combined organic extracts were washed with brine and dried over magnesium sulfate. After concentration *in vacuo*, the residue was chromatographed (ethyl acetate-hexane 1:3) to afford the title alcohol as an oil.


<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): 7.27 (m, 2H); 6.89 (m, 2H); 4.79 (s, 1H); 4.44 (s, 2H); 3.91 (m, 4H); 3.81 (s, 3H); 3.68 (t, *J* = 5.4Hz, 1H); 3.44 (m, 2H); 3.32 (m, 1H); 2.07 (m, 1H); 1.59 (br s, 1H); 1.33 (d, *J* = 11.4Hz, 3H); 1.31 (s, 3H), 1.29 (s, 3H), 1.03 (d, *J* = 6.9Hz, 3H).



(5*S*,6*R*)-6-[(1'*S*)-2'-(4-Methoxy-benzyloxy)-1'-methyl-ethyl]-3,3,5-trimethyl-[1,4]-oxathian-2-ol

To a solution of ketal (1.15g, 3mmol) in tetrahydrofuran (12mL) was added 2M H<sub>2</sub>SO<sub>4</sub> (2.8mL). The reaction mixture was heated at 60°C for 3h. The reaction mixture was cooled down. Water (10mL) and ether (30mL) were added. The aqueous layer was discarded and the organic layer was washed with water until pH = 7 was reached. The organic layer was then filtered through hydromatrix (Sat NaHCO<sub>3</sub>, water) and the filtrate was concentrated *in vacuo*. The residue was then chromatographed (hexane-ethyl acetate 4-1 then 2-1) to afford the hemiacetal (0.970g, 2.84mmol) as an oil.

$^1\text{H}$  NMR (300MHz,  $\text{CDCl}_3$ ) main epimer: 7.23 (m, 2H); 6.87 (m, 2H); 4.75 (d,  $J=5.4\text{Hz}$ , 1H); 4.40 (dd, AB,  $J=11.7, 15.3\text{Hz}$ , 2H); 3.85 (dd,  $J=2.4, 9.6\text{Hz}$ , 1H); 3.80 (s, 3H); 3.30 (app qd,  $J=5.1, 9.6\text{Hz}$ , 2H); 2.69 (d,  $J=5.7\text{Hz}$ , 1H); 2.65 (qd,  $J=2.4, 7.2\text{Hz}$ , 1H); 1.89 (m, 1H); 1.48 (s, 3H); 1.44 (d,  $J=7.2\text{Hz}$ , 3H); 1.16 (s, 3H); 1.1 (d,  $J=6.6\text{Hz}$ , 3H).



**(3RS)-3-Hydroxy-4-[(1'R,2'S,3'R)-2'-hydroxy-4'-(4-methoxybenzyloxy)-1',3'-dimethyl-butylsulfanyl]-4-methyl-pentanoic acid tert-butyl ester**


To a solution of diisopropylamine (5.1mL, 36.4mmol) in tetrahydrofuran (90mL) was added at  $-78^\circ\text{C}$ ,  $n\text{-BuLi}$  (14mL, 2.3N in hexanes, 32.2mmol). The solution was stirred 5 minutes at this temperature and then 10 minutes at  $0^\circ\text{C}$ . After cooling to  $-78^\circ\text{C}$ , tert-butyl acetate (5.6mL, 41.5mmol) was added drop wise over 15 minutes. The resulting mixture was then stirred 1 h at the same temperature and a solution of lactol (1.5g, 4.4mmol) in tetrahydrofuran (3mL+1mL rinse) was added. The mixture was then stirred 15 minutes at  $-78^\circ\text{C}$ , and the reaction mixture was warmed to  $0^\circ\text{C}$ . The reaction proceeded at this temperature for 2h and then 1h at room temperature. The reaction was quenched by



adding water. The reaction mixture was extracted with ethyl acetate (2 x 100mL). The combined organic layers were dried over sodium sulfate and concentrated *in vacuo*. The residue was chromatographed over silica gel (hexane-ethyl acetate 3-1) to afford the title ester (1.15g, 2.51mmol) as an oil.

MS (ESI,  $m/z$ ) : 457.9  $[M+H^+]$

$^1H$  NMR (300MHz,  $CDCl_3$ ): 7.25 (m, 2H); 6.86 (m, 2H); 4.42 (br s, 2H); 3.91 (two dd, 1H); 3.81 (two s, 3H); 3.67 (m, 1H); 3.66 (m, 2H); 3.17 (m, 1H); 2.58 (td, 1H); 2.40 (m, 1H); 2.2 (br s, 2OH); 2.06 (m, 1H); 1.46 (two s, 9H); 1.30-1.25 (m, 9H); 1.12 (m, 3H).




(3*RS*)-3-(*tert*-Butyl-dimethyl-silanyloxy)-4-[(1'*R*,2'*S*,3'*S*)-2'-(*tert*-butyl-dimethyl-silanyloxy)-4'-(4-methoxy-benzyloxy)-1',3'-dimethyl-butylsulfanyl]-4-methyl-pentanoic acid *tert*-butyl ester

To a solution of diol (1.15 g, 2.51mmol) in dichloromethane (18mL), cooled to -78C, were added 2,6-lutidine (2mL 2.88mL,

24.76mmol) and *tert*-Butyldimethylsilyl trifluoromethane-sulfonate (3.45mL, 15mmol). The reaction mixture was then stirred 15 minutes at this temperature and then warmed up to 0°C. The reaction proceeded for 1h, and was diluted with diethyl ether (150mL) and saturated CuSO<sub>4</sub> (30mL). The organic layer was then further washed with saturated CuSO<sub>4</sub> (5 x 30mL), water (30mL) and brine (30mL). After drying over sodium sulfate and evaporation to dryness. The title crude compound was recovered as a yellowish oil around (2.2 g). This material was carried on without further purification.


<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): 7.26 (m, 2H); 6.89 (m, 2H); 4.42 (br, s, 2H); 4.19 (m, 0.6H); 4.12 (m, 0.4H); 3.80 (s and overlapped m, 3.6H); 3.74 (m, 0.4H); 3.44-3.2 (m, 4H); 2.36-2.25 (m, 1H); 2.13 (m, 1H); 1.44 (two s, 3H); 1.24 (m, 6H); 0.98-0.86 (m, 30H); 0.28-0.02 (m, 12H).



(3*RS*)-3-(*tert*-Butyl-dimethyl-silanyloxy)-4-[(1'*R*,2'*S*,3'*S*)-2'-(*tert*-butyl-dimethyl-silanyloxy)-4'-hydroxy-1',3'-dimethyl-butylsulfanyl]-4-methyl-pentanoic acid *tert*-butyl ester

To a solution of ester (2.2g, crude, 2.51mmol) in dichloromethane (17mL) and water (1mL) was added 2,3-dichloro-5,6-dicyano-*p*-benzoquinone (DDQ) (0.72 g, 3.17mmol). The reaction was stirred at room temperature for 30 minutes and diethyl ether (250mL) and saturated NaHCO<sub>3</sub> (50mL) were added. The organic layer was further washed with saturated NaHCO<sub>3</sub> until clear aqueous layer was obtained. The organic layer was washed with brine and dried over sodium sulfate. After evaporation to dryness, the residue was chromatographed (hexane-ethyl acetate 9-1) to afford the title alcohol (1.4g, 2.47mmol) as an oil.


<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): 4.18 (dd, *J*= 2.7, 6.6Hz, 0.5H); 4.13 (td, *J*= 3.3, 6.9Hz, 0.5H);, 3.86 (m, 1H); 3.55 (m, 2H); 3.25 (ddd, *J*= 2.4, 17.4, 34.5Hz, 0.5H), 3.21 (dd, *J*= 2.4, 17.1Hz, 0.5H), 3.06 (m, 1H); 2.29 (m, 1H); 2.1 (m, 0.5H); 1.95 (m, 0.5H), 1.46 (s, 6H); 1.35-1.15 (m, 6H); 0.98-0.89 (m, 27H); 0.2-0.03 (m, 12H).



(3*RS*)-3-(*tert*-Butyl-dimethyl-silanyloxy)-4-[(1'*R*,2'*S*,3'*S*)-2'-(*tert*-butyl-dimethyl-silanyloxy)-1,3-dimethyl-4-oxo-butylsulfanyl]-4-methyl-pentanoic acid *tert*-butyl ester

To a solution of oxalyl chloride (0.59mL, 7mmol) in dichloromethane (6mL) cooled to -78C, was added a solution of DMSO (0.6mL, 8.4mmol) in dichloromethane (6mL). The reaction was stirred 15 minutes at room temperature and a solution of alcohol (1.4 g), 2.47mmol) in dichloromethane (5mL+2mL rinse) was added. After stirring for one hour at the same temperature, a solution of diisopropylethylamine (3mL, 17.52mmol) in dichloromethane (3mL) was added. The reaction was stirred for 20 minutes and then was warmed to 0C. after stirring 30 minutes, TLC showed that the reaction was done. The reaction mixture was filtered through hydromatrix and the filtrate was concentrated in vacuo. The residue was then chromatographed (hexane-ethyl acetate 9-1) to afford the title compound (1.22 g, 2.16 mmol) as an oil. The aldehyde was immediately used in the next step without characterization.


Completion of the Synthesis:



(3*RS*)-4-[(1'*R*,2'*S*,3'*S*,4'*Z*,7'*Z*,10'*S*,11'*E*)-2',10'-Bis-(tert-butyl-dimethyl-silanyloxy)-1',3',7',11'-tetramethyl-12'-(2-methyl-thiazol-4-yl)-dodeca-4',7',11'-trienylsulfanyl]-3-(tert-butyl-dimethyl-silanyloxy)-4-methyl-pentanoic acid tert-butyl ester

To a solution of [(6*S*)-6-(*tert*-Butyl-dimethyl-silanyloxy)-3,7-dimethyl-8-(2-methyl-1,3-thiazol-4-yl)-octa-3,7-dienyl]-triphenyl-phosphonium bromide (2.57g, 3.64mmol) in tetrahydrofuran (47mL) cooled to -78C, was added a solution of lithium bis trimethylsilyl amide (3.5mL, 1.06M in tetrahydrofuran, 3.71mmol). The mixture was then stirred for 1 h at -78C. A solution of aldehyde (1.2g, 2.13mmol) in tetrahydrofuran (5mL + 3mL rinse) was added dropwise to the mixture. The reaction was stirred for one hour at - 78 C and warmed up to 0 C. The reaction mixture was then stirred for 1h. No more evolution was stated by TLC. The reaction mixture was quenched by adding MeOH (5mL). Sodium borohydride (0.4g, 10.6mmol) was added to reduce the remaining aldehyde, The mixture was stirred for 20 minutes. Water (40 mL) was then added and the two phases were diluted with ethyl acetate and separated. The aqueous layer was extracted with ethyl acetate (4 x 50mL). The combined organic layers were washed with brine and dried over sodium sulfate. The filtrate was concentrated in *vacuo* and chromatographed (ethyl acetate-hexane 1:30) to afford the title compound (1.0g, 1.1 mmol) as an oil.

<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): 6.92 (s, 1H); 6.48 (s, 1H); 5.53 (m, 0.5H); 5.31-5.14 (m, 2.5H); 4.11 (m, 2H); 3.58 (m, 1H); 3.21 (m, 1H); 3.01 (m, 1H); 2.83-2.78 (m, 2H); 2.72 (s, 3H); 2.70 (m, 0.5H); 2.34-2.12 (m, 3.5H); 2.00 (s, 3H); 1.67 (s, 3H); 1.46 (s, 4.5H); 1.44 (s, 4.5H); 1.43 (s, 1.5H); 1.33 (s, 1.5H); 1.18 (overlapped signals, 3H); 1.10 (s, 3H); 1.00 (d, J= 7.0Hz, 3H); 0.92 (s, 4.5H); 0.91 (s, 4.5H); 0.88 (s, 9H); 0.86 (s, 9H); 0.19 (s, 1.5H); 0.18 (s, 1.5H); 0.1-0.001 (several s, 15H).



(3R)-4-[(1'R,2'S,3'S,4'Z,7'Z,10'S,11'E)-2',10'-Bis-(tert-butyl-dimethyl-silyloxy)-1',3',7',11'-tetramethyl-12'-(2-methyl-thiazol-4-yl)-dodeca-4',7',11'-trienylsulfanyl]-3-(tert-butyl-dimethyl-silyloxy)-4-methyl-pentanoic acid and (3S)-4-[(1'R,2'S,3'S,4'Z,7'Z,10'S,11'E)-2',10'-Bis-(tert-butyl-dimethyl-silyloxy)-1',3',7',11'-tetramethyl-12'-(2-methyl-thiazol-4-yl)-dodeca-4',7',11'-trienylsulfanyl]-3-(tert-butyl-dimethyl-silyloxy)-4-methyl-pentanoic acid


To an ice-chilled solution of substrate (1.0g, 1.1mmol) in dichloromethane (78mL) were added 2,6-lutidine (1.63mL, 14.1mmol) and then trimethylsilyl trifluoromethanesulfonate (1.27mL, 7mmol). The reaction was stirred at the same temperature for 1h. The reaction mixture was then warmed up to room temperature and further stirred for 3h. The reaction mixture was then diluted with diethyl ether (300mL). The organic layer was washed with a saturated solution of copper sulfate (5 x 80mL), brine (80mL) and dried over magnesium sulfate. The residue was chromatographed (hexane-ethyl acetate 9-1) to afford a first eluting isomer (0.400g, 0.468mmol) as an oil.

<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): 6.97 (s, 1H); 6.80 (s, 1H); 5.37-5.3 (m, 3H); 4.26 (dd, J= 1.8, 7.8Hz, 1H); 4.21 (dd, J= 4.5, 9.0Hz,

1H); 3.65 (d, J= 9.3Hz, 1H); 3.40 (dd, J= 1.8, 16.0Hz, 1H); 3.20 (app q, J= 6.9Hz, 1H); 3.11 (m, 1H); 2.75-2.64 (m, 2H); 2.74 (m, 2H); 2.34 (dd, J= 7.8, 16.0Hz, 1H); 2.30 (m, 2H); 1.94 (s, 3H); 1.67 (s, 3H); 1.41 (s, 3H); 1.17 (d, J= 7.2Hz, 3H); 1.10 (s, 3H); 1.01 (d, J= 6.6Hz, 3H); 0.93 (s, 9H); 0.90 (s, 9H), 0.86 (s, 9H); 0.23 (s, 3H); 0.14 (s, 3H); 0.06 (s, 3H); 0.01 (s, 6H); -0.01 (s, 3H).

Further elution was then performed (Hexane-Ethyl acetate 6-1) to give a second eluting isomer (0.4g, 0.468mmol) as an oil.

<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): 6.93 (s, 1H); 6.48 (s, 1H); 5.40-5.2 (m, 2H); 4.14-4.09 (m, 2H); 3.61 (dd, J= 1.8, 8.4Hz, 1H); 3.31 (dd, J= 2.1, 16.5Hz, 1H); 3.01 (qd, J= 1.8, 7.2Hz, 1H); 2.78 (m, 2H); 2.73 (s, 3H); 2.67 (m, 1H); 2.41 (dd, J= 7.8; 16.5Hz, 1H); 2.30 (m, 2H); 1.94 (s, 3H); 1.67 (s, 3H); 1.44 (s, 3H); 1.17 (d, J= 7.2Hz, 3H); 1.10 (s, 3H); 1.00 (d, J= 6.6Hz, 3H); 0.93 (s, 9H); 0.89 (s, 9H); 0.87 (s, 9H);, 0.19 (s, 3H); 0.11 (s, 3H); 0.10 (s, 3H); 0.07 (s, 3H); 0.05 (s, 3H); 0.02 (s, 3H).




(3R)-3-(tert-Butyl-dimethyl-silanyloxy)-4-  
 [(1'R,2'S,3'S,4'Z,7'Z,10'S,11'E)-2'-(tert-butyl-dimethyl-  
 silanyloxy)-10'-hydroxy-1',3',7',11'-tetramethyl-12'-(2-methyl-

thiazol-4-yl)-dodeca-4',7',11'-trienylsulfanyl]-4-methyl-pentanoic acid

To an ice cooled solution of substrate (0.2g, 0.234mmol) in tetrahydrofuran (5mL) was added TBAF (2.2mL, 1M in tetrahydrofuran, 2.2mmol). The reaction was stirred 2h at room temperature. The reaction mixture was diluted with 10% solution of NaHSO<sub>4</sub> and extracted with ethyl acetate (5 x 50mL). The combined organic layers were washed with brine and dried over sodium sulfate. After evaporation, the residue was chromatographed (dichloromethane-methanol 19-1) to afford the title compound (0.130g, 0.1756mmol) as a foam.

<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): 6.97 (s, 1H); 6.88 (s, 1H); 5.37-5.29 (m, 3H); 4.23 (dd, J= 1.8, 8.1Hz, 1H); 4.19 (dd, J= 3.9, 9.4Hz, 1H); 3.63 (d, J= 8.4Hz, 1H); 3.42 (dd, J= 1.8, 16.2Hz, 1H); 3.23-3.15 (m, 2H); 2.75 (m, 1H); 2.73 (s, 3H); 2.69 (m, 1H); 2.50-2.34 (m, 2H); 2.33 (dd, J= 7.8, 15.9Hz, 1H); 1.98 (s, 3H); 1.73 (s, 3H); 1.40 (s, 3H); 1.17 (d, J= 7.2Hz, 3H); 1.10 (s, 3H); 1.0 (d, J= 6.6Hz, 3H); 0.93 (s, 9H); 0.85 (s, 9H), 0.22 (s, 3H); 0.13 (s, 3H); 0.07 (s, 3H); -0.01 (s, 3H).




(3S)-3-(tert-Butyl-dimethyl-silanyloxy)-4-  
[(1'R,2'S,3'S,4'Z,7'Z,10'S,11'E)-2'-(tert-butyl-dimethyl-



silanyloxy)-10'-hydroxy-1',3',7',11'-tetramethyl-12'-(2-methyl-thiazol-4-yl)-dodeca-4',7',11'-trienylsulfanyl]-4-methyl-pentanoic acid

To an ice cooled solution of substrate (0.2g, 0.234mmol) in tetrahydrofuran (5mL) was added TBAF (2.2mL, 1M in tetrahydrofuran, 2.2mmol). The reaction was stirred 2h at room temperature. The reaction mixture was diluted with 10% solution of NaHSO<sub>4</sub> and extracted with Ethyl acetate (5 x 50mL). The combined organic layers were washed with brine and dried over sodium sulfate. After evaporation, the residue was chromatographed (DCM-MeOH 19-1) to afford the title compound (0.139g, 0.1877mmol) as a foam.


<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): 6.97 (s, 1H); 6.62 (s, 1H); 5.45-5.21 (m, 3H); 4.20-4.12 (m, 2H); 3.59 (dd, J= 2.1, 7.8Hz, 1H); 3.30 (dd, J= 2.1, 16.8Hz, 1H); 3.01 (qd, J= 1.8, 7.2Hz, 1H); 2.90-2.82 (m, 2H); 2.74 (s, 3H); 2.72 (m, 1H); 2.45-2.37 (m, 3H); 2.02 (s, 3H); 1.73 (s, 3H); 1.42 (s, 3H); 1.18 (d, J= 7.2Hz, 3H); 1.10 (s, 3H); 1.00 (d, J= 6.6Hz, 3H); 0.93 (s, 9H), 0.88 (s, 9H), 0.17 (s, 3H), 0.10 (s, 3H); 0.08 (s, 3H), 0.02 (s, 3H).



(4R,7R,8S,9S,10Z,13Z,16S)-4,8-Bis-(tert-butyl-dimethyl-silanyloxy)-5,5,7,9,13-pentamethyl-16-[(E)-1-methyl-2-(2-methyl-1,3-thiazol-4-yl)-ethenyl]-1-oxa-6-thia-cyclohexadeca-10,13-dien-2-one

To an ice cooled solution of substrate (0.135g, 0.18mmol) in tetrahydrofuran (3 mL) was added triethylamine (0.151mL, 1.08mmol) and then 2,4,6-trichlorobenzoylchloride (0.067mL, 0.428mmol). The reaction was stirred at 0C for one hour. The reaction mixture was then added using a syringe pump to a solution of 4-DMAP (0.051g, 0.416mmol) in toluene (37 mL) at 70C over 2h. After the addition was completed, the reaction was stirred 30 minutes at the same temperature. After cooling, the reaction mixture was evaporated to dryness. The residue was then filtered through a plug of silica gel (hexane-diethyl ether 1:1) to eliminate solids. The filtrate was concentrated in vacuo and the residue was purified by chromatography (hexane-ethyl acetate 19:1) to afford the title compound (0.093g, 0.128mmol) as a colorless oil.

<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): 6.91 (s, 1H); 6.40 (s, 1H); 5.45 (td, J= 5.1, 11Hz, 1H); 5.36 (t app, J= 4.2Hz, 1H); 5.31-5.23 (m, 2H); 4.20 (dd, J= 2.4, 7.8Hz, 1H); 3.67 (dd, J= 2.7, 5.1Hz, 1H); 3.33 (dd, J= 9.6, 15.3Hz, 1H); 3.12 (qd, J= 2.7, 7.2Hz, 1H); 2.91 (dd, J= 7.8, 15.9Hz, 1H); 2.81 (m, 1H); 2.72 (s, 3H); 2.58-2.49 (m, 3H); 2.46 (dd, J= 2.7, 15.9Hz, 1H); 2.16 (s, 3H); 1.77 (s, 3H); 1.39 (s, 3H); 1.21 (d, J= 7.2Hz, 3H); 1.19 (s, 3H); 1.00 (d, J= 6.6Hz, 3H); 0.93 (s, 9H); 0.91 (s, 9H), 0.09 (s, 3H), 0.06 (s, 3H); 0.03 (s, 3H); 0.01 (s, 3H).




(4*S*,7*R*,8*S*,9*S*,10*Z*,13*Z*,16*S*)-4,8-Bis-(*tert*-butyl-dimethyl-silanyloxy)-5,5,7,9,13-pentamethyl-16-[(*E*)-1-methyl-2-(2-methyl-1,3-thiazol-4-yl)-ethenyl]-1-oxa-6-thia-cyclohexadeca-10,13-dien-2-one

To an ice cooled solution of substrate (0.130g, 0.18mmol) in tetrahydrofuran (3mL) was added triethylamine (0.151mL, 1.08mmol) and then 2,4,6-trichlorobenzoylchloride (0.067mL, 0.428mmol). The reaction was stirred at 0C for one hour. The reaction mixture was then added using a syringe pump to a solution of 4-DMAP (0.051g, 0.416mmol) in toluene (37mL) at 70°C over 2h. After the addition was completed, the reaction was stirred 30 minutes at the same temperature. After cooling, the reaction mixture was evaporated to dryness. The residue was then filtered through a plug of silica gel (hexane-diethyl ether 1:1) to eliminate solids. The filtrate was concentrated *in vacuo* and the residue was purified by chromatography (hexane-ethyl acetate 19:1) to afford the title compound (0.114g, 0.128mmol) as a colorless oil.

<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): 6.98 (s, 1H), 5.54 (s, 1H), 5.41-5.21 (m, 3H); 5.07 (t app, J= 7.2Hz, 1H); 4.30 (dd, J= 3.6, 6.0Hz, 1H); 3.33 (m, 2H); 2.99-2.77 (m, 4H); 2.73 (s, 3H); 2.53-2.37

(m, 3H); 2.11 (s, 3H), 1.77 (s, 3H), 1.44 (s, 3H), 1.36 (d, J= 6.9Hz, 3H); 1.14 (s, 3H); 1.00 (d, J= 6.6Hz, 3H), 0.93 (s, 9H), 0.87 (s, 9H), 0.15 (s, 3H); 0.07 (s, 3H), 0.04 (s, 3H), 0.03 (s, 3H).




(4*R*,7*R*,8*S*,9*S*,10*Z*,13*Z*,16*S*)-4,8-Dihydroxy-5,5,7,9,13-pentamethyl-16-[(*E*)-1-methyl-2-(2-methyl-1,3-thiazol-4-yl)-ethenyl]-1-oxa-6-thia-cyclohexadeca-10,13-dien-2-one

To an ice chilled solution of substrate (0.076g, 0.105mmol) in tetrahydrofuran (3mL) were added a stock solution of HF-pyridine (7mL, prepared by diluting HF.pyridine (4mL) in a solution of pyridine (11.4mL) in tetrahydrofuran (20mL)) and HF.pyridine (1.8mL). After stirring for 30 minutes at 0C, the solution was heated at 45C for 30h. The reaction mixture was cooled down and the reaction was poured onto a saturated solution of NaHCO<sub>3</sub> (50mL). The pH was adjusted to 8 by adding solid sodium bicarbonate. The aqueous layer was extracted with ethyl acetate (4 x 50mL) and the combined organic layers were washed with a saturated solution of copper sulfate (5 x 25mL). The organic layer was then dried over sodium sulfate and concentrated in vacuo. The residue was chromatographed (hexane-ethyl acetate 1:1) to afford the title compound (0.048g, 0.0972mmol) as an oil.

MS (ESI,  $m/z$ ): 494.5  $[M+H]^+$

$^1H$  NMR (300MHz,  $CDCl_3$ ): 6.98 (s, 1H); 6.55 (s, 1H), 5.51-5.34 (m, 3H); 5.08 (m, 1H); 4.24 (m, 1H); 3.86 (br s, 1H); 3.49 (m, 1H); 3.33 (qd,  $J = 4.2, 7.2$ Hz, 1H); 3.06 (dd,  $J = 6.0, 15.3$ Hz, 1H); 2.93-2.74 (m, 5H); 2.73 (s, 3H); 2.61 (dd,  $J = 5.4, 15.6$ Hz, 1H); 2.41 (m, 1H); 2.12 (s, 3H); 1.72 (s, 3H); 1.51 (s, 3H); 1.36 (d,  $J = 7.2$ Hz, 3H); 1.27 (s, 3H); 1.07 (d,  $J = 6.6$ Hz, 3H).




(4*S*,7*R*,8*S*,9*S*,10*Z*,13*Z*,16*S*)-4,8-Dihydroxy-5,5,7,9,13-pentamethyl-16-[(*E*)-1-methyl-2-(2-methyl-1,3-thiazol-4-yl)-ethenyl]-1-oxa-6-thia-cyclohexadeca-10,13-dien-2-one

To an ice chilled solution of substrate (0.04g, 0.055mmol) in tetrahydrofuran (3mL) were added a stock solution of HF-pyridine (6mL, prepared by diluting HF.pyridine (4mL) in a solution of pyridine (11.4mL) in tetrahydrofuran (20mL)) and HF.pyridine (1mL). After stirring for 30 minutes at 0C, the solution was heated at 45C for 30h. The reaction mixture was cooled down and the reaction was poured onto a saturated solution of  $NaHCO_3$  (50 mL). The pH was adjusted to 8 by adding solid sodium bicarbonate. The aqueous layer was extracted with ethyl acetate (4 x 50mL) and the combined organic layers were

washed with a saturated solution of copper sulfate (5 x 25mL). The organic layer was then dried over sodium sulfate and concentrated in vacuo. The residue was chromatographed (hexane-ethyl acetate 1:1) to afford the title compound (0.025g, 0.0506mmol) as an oil.

MS (ESI, m/z): 494.5 [M+H<sup>+</sup>]

<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): 6.98 (s, 1H); 6.50 (s, 1H); 5.49-5.4 (m, 3H); 5.13 (t, J= 7.8Hz, 1H); 4.08 (m, 1H); 3.38 (m, 1H); 3.13-2.93 (m, 3H); 2.88 (dd, J= 3.6Hz, 1H); 2.81 (m, 1H); 2.72 (s, 3H), 2.66 (dd, J= 3.3, 15.3Hz, 1H); 2.54 (dd, J= 5.1, 8.1Hz, 1H); 2.46 (dd, J= 8.4, 15.6Hz, 1H); 2.10 (s, 3H); 2.0 (m, 1H); 1.74 (s, 3H); 1.43 (s, 3H); 1.38 (d, J= 6.9Hz, 3H); 1.28 (s, 3H); 1.08 (d, J= 6.9Hz, 3H).




(4R,7R,8S,9S,10Z,13Z,16S)-4,8-Dihydroxy-5,5,7,9,13-pentamethyl-16-[(E)-1-methyl-2-(2-methyl-1,3-thiazol-4-yl)-ethenyl]-1-oxa-6-thia-cyclohexadec-13-en-2-one

To a solution of substrate (0.047g, 0.095mmol) in diethyl ether (3mL) were added triethylamine (0.09mL, 0.65mmol) and triisopropylbenzenesulfonyl hydrazine (0.180g, 0.6mmol). The mixture was heated at 37C for 3h. The reaction mixture was cooled and the solids were filtered off through a pad of silica gel using ether as an eluent. After concentration in vacuo, the residue was subjected to the reaction conditions previously described. This operation was repeated six times. After these

cycles, the residue was purified by chromatography (hexane-ethyl acetate 1-2) to afford the title compound (0.030g, 0.06mmol) as an oil.

MS (ESI,  $m/z$ ): 496.5  $[M+H]^+$

$^1H$  NMR (300MHz,  $CDCl_3$ ): 6.98 (s, 1H); 6.61 (s, 1H); 5.30 (dd,  $J = 1.5, 7.2$ Hz, 1H); 5.12 (m, 1H); 4.14 (dd, 1H); 3.55 (dd,  $J = 1.8, 9.0$ Hz, 1H); 3.39 (qd,  $J = 1.8, 7.2$ Hz, 1H); 2.80-2.60 (m, 3H); 2.72 (s, 3H); 2.4-2.35 (m, 2H); 2.33-2.20 (m, 2H); 2.08 (s, 3H); 1.92 (m, 1H); 1.69 (s, 3H); 1.58-1.42 (m, 4H); 1.42 (s, 3H); 1.30 (s, 3H); 1.22 (d,  $J = 6.6$ Hz, 3H); 1.06 (d,  $J = 6.6$ Hz, 3H).




(4*S*,7*R*,8*S*,9*S*,10*Z*,13*Z*,16*S*)-4,8-Dihydroxy-5,5,7,9,13-pentamethyl-16-[(*E*)-1-methyl-2-(2-methyl-1,3-thiazol-4-yl)-ethenyl]-1-oxa-6-thia-cyclohexadec-13-en-2-one

To a solution of substrate (0.025g, 0.0506mmol) in diethyl ether (1.5mL) were added triethylamine (0.044mL, 0.32mmol) and triisopropylbenzenesulfonyl hydrazine (0.088g, 0.3mmol). The mixture was heated at 37C for 3h. The reaction mixture was cooled and the solids were filtered off through a pad of silica gel using ether as an eluent. After concentration in vacuo, the residue was subjected to the reaction conditions previously described. This operation was repeated six times. After these cycles, the residue was purified by chromatography (hexane-

ethyl acetate 1-2) to afford the title compound (0.015g, 0.030mmol) as an oil.

MS (ESI,  $m/z$ ): 496.4 [ $M+H^+$ ]

$^1H$  NMR (300MHz,  $CDCl_3$ ): 6.98 (s, 1H); 6.50 (s, 1H); 5.42 (dd,  $J=2.9, 7.2$ Hz, 1H); 5.16 (t,  $J=6.9$ Hz, 1H); 4.02 (td,  $J=1.5, 9.7$ Hz, 1H); 3.50 (m, 1H); 3.18 (qd,  $J=2.4, 7.0$ Hz, 1H); 3.11 (d,  $J=2.5$ Hz, 1H); 2.89 (dd,  $J=2.5, 14.8$ Hz, 1H); 2.72 (s, 3H); 2.56-2.46 (m, 2H); 2.41 (dd,  $J=10, 14.9$ Hz, 1H); 2.12-1.95 (m, 3H); 2.08 (s, 3H); 1.69 (s, 3H); 1.62 (br s, 1H); 1.46-1.20 (m, 4H); 1.38 (s, 3H); 1.32 (s, 3H); 1.27 (d,  $J=6.6$ Hz, 3H); 1.05 (d,  $J=6.6$ Hz, 3H).




(4*R*,7*R*,8*S*,9*S*,10*Z*,13*Z*,16*S*)-4,8-Dihydroxy-5,5,7,9,13-pentamethyl-16-[(*E*)-1-methyl-2-(2-methyl-1,3-thiazol-4-yl)-ethenyl]-6,6-dioxo-1-oxa-6 $\lambda^6$ -thia-cyclohexadec-13-en-2-one

To a solution of substrate (0.005g, 0.01mmol) in dichloromethane (0.3mL) was added at -78C, 3-chloroperoxybenzoic acid (0.0042g, 0.024mmol). The reaction mixture was then stirred at the same temperature for 20 minutes. The reaction mixture was directly chromatographed (hexane-ethyl acetate 1-3) to afford the title compound (0.0032g, 0.006mmol) as an oil.



MS (ESI,  $m/z$ ): 528.0  $[M+H]^+$

$^1H$  NMR (300MHz,  $CDCl_3$ ): 6.99 (s, 1H); 6.75 (s, 1H); 5.49 (dd,  $J = 1.5, 10.2$ Hz, 1H); 5.13 (m, 1H); 4.31-4.15 (m, 2H); 3.96 (m, 1H); 3.38 (br s, 1H); 2.92-2.70 (m, 2H); 2.73 (s, 3H); 2.59 (m, 1H); 2.4 (m, 1H); 2.35-1.92 (m, 4H); 2.11 (s, 3H); 1.66 (s, 3H), 1.65-1.3 (m, 4H); 1.56 (s, 3H) 1.43-1.40 (s and d overlapped, 6H); 1.12 (d,  $J = 6.6$ Hz, 3H).




(4*S*,7*R*,8*S*,9*S*,10*Z*,13*Z*,16*S*)-4,8-Dihydroxy-5,5,7,9,13-pentamethyl-16-[(*E*)-1-methyl-2-(2-methyl-1,3-thiazol-4-yl)-ethenyl]-6,6-dioxo-1-oxa-6 $\lambda^6$ -thia-cyclohexadec-13-en-2-one

To a solution of substrate (0.005g, 0.01mmol) in dichloromethane (0.3mL) was added at -78C, 3-chloroperoxybenzoic acid 0.0042g, 0.024mmol). The reaction mixture was then stirred at the same temperature for 20 minutes. The reaction mixture was directly chromatographed (hexane-ethyl acetate 1-3) to afford the title compound (0.0030g, 0.0056mmol) as an oil.

MS (ESI,  $m/z$ ): 528.0  $[M+H]^+$

$^1H$  NMR (300MHz,  $CDCl_3$ ): 6.99 (s, 1H); 6.55 (s, 1H); 5.49 (dd,  $J = 2.3, 9.6$ Hz, 1H); 5.13 (m, 1H); 4.50 (td,  $J = 2.8, 10.8$ Hz, 1H); 4.22 (d,  $J = 9.5$ Hz, 1H); 4.05 (q,  $J = 7.5$ Hz, 1H); 3.38 (br s, 1H); 2.78-2.72 (m, 1H); 2.65-2.49 (m, 2H), 2.42 (br s, 1H);

2.36-2.28 (m, 2H); 2.11 (s, 3H), 2.10 (m, 1H); 1.90 (m, 1H); 1.70 (s, 3H); 1.58-1.30 (m, 4H); 1.46-1.42 (s and d overlapped, 6H); 1.37 (s, 3H); 1.09 (d,  $J = 6.6\text{Hz}$ , 3H).




(4*R*,7*R*,8*S*,9*S*,10*Z*,13*Z*,16*S*)-4,8-Dihydroxy-5,5,7,9,13-pentamethyl-16-[(*E*)-1-methyl-2-(2-methyl-1,3-thiazol-4-yl)-ethenyl]-6-oxo-1-oxa-6 $\lambda^6$ -thia-cyclohexadec-13-en-2-one

To a solution of substrate (0.009g, 0.0181mmol) in dichloromethane (0.5mL) was added at -78C, 3-chloroperoxybenzoic acid (0.0037 g, 0.022mmol). The reaction was stirred at the same temperature for 10 minutes and 10% sodium metabisulfite (0.1mL) was added. After warming up to room temperature, the mixture was directly purified by chromatography (hexane-ethyl acetate 1-2) to afford the title compound (0.0034g, 0.0066mmol) as an oil

MS (ESI,  $m/z$ ): 512.5[M+H<sup>+</sup>]

<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): 6.96 (s, 1H); 6.55 (s, 1H); 5.29 (dd,  $J = 2.4, 9.5\text{Hz}$ , 1H); 5.16 (m, 1H); 5.00 (br s, 1H); 4.83 (t,  $J = 6.9\text{Hz}$ , 1H), 4.1 (d,  $J = 9.3\text{Hz}$ , 1H); 3.50 (m, 1H); 3.00 (br s, 1H); 2.73 (s, 3H); 2.73-2.51 (m, 2H); 2.43-2.20 (m, 3H); 2.10 (s, 3H); 1.96 (m, 1H); (m, 1H); 1.66 (s, 6H); 1.61 (d, 3H), 1.60-1.3 (m, 4H); 1.42 (d,  $J = 7.2\text{Hz}$ , 3H), 1.15 (d,  $J = 6.3\text{Hz}$ , 3H); 1.07 (s, 3H).




(4*S*,7*R*,8*S*,9*S*,10*Z*,13*Z*,16*S*)-4,8-Dihydroxy-5,5,7,9,13-pentamethyl-16-[(*E*)-1-methyl-2-(2-methyl-1,3-thiazol-4-yl)-ethenyl]-6-oxo-1-oxa-6 $\lambda^6$ -thia-cyclohexadec-13-en-2-one

To a solution of substrate (0.005g, 0.01mmol) in dichloromethane (0.5mL) was added at -78C, 3-chloroperoxybenzoic acid (0.0024 g, 0.012mmol). The reaction was stirred at the same temperature for 10 minutes and 10% sodium metabisulfite (0.1mL) was added. After warming up to room temperature, the mixture was directly purified by chromatography (hexane-ethyl acetate 1-2) to afford the title compound (0.0021g, 0.0041mmol) as an oil

MS (ESI,  $m/z$ ): 496.5 [ $M+H^+$ ]

$^1\text{H}$  NMR (300MHz,  $\text{CDCl}_3$ ): 6.99 (s, 1H); 6.57 (s, 1H); 5.50 (m, 1H); 5.12 (m, 1H); 4.31 (d,  $J=10.2\text{Hz}$ , 1H); 4.06 (d,  $J=9.9\text{Hz}$ , 1H); 3.58 (q,  $J=7.4\text{Hz}$ , 1H); 3.33 (br s, 1H); 3.20 (br s, 1H); 2.79 (d,  $J=15.4\text{Hz}$ , 1H); 2.73 (s, 3H); 2.62-2.43 (m, 3H); 2.19-1.94 (m, 3H); 2.10 (s, 3H); 1.66 (s, 3H); 1.50-1.35 (m, 4H); 1.43 (d,  $J=7.2\text{Hz}$ , 3H); 1.37 (s, 3H); 1.33 (s, 3H); 1.06 (d,  $J=6.6\text{Hz}$ , 3H).




(4*S*, 7*R*, 8*S*, 9*S*, 10*Z*, 13*Z*, 16*S*)-4,8-Dihydroxy-5,5,7,9,13-pentamethyl-16-[(*E*)-1-methyl-2-(2-methyl-1,3-thiazol-4-yl)-ethenyl]-6-oxo-1-oxa-6 $\lambda^6$ -thia cyclohexadec-10,13-dien-2-one

To a solution of substrate (0.010g, 0.02mmol) in dichloromethane (0.5mL) was added at -78C, 3-chloroperoxybenzoic acid (0.0024 g, 0.012mmol). The reaction was stirred at the same temperature for 10 minutes and 10% sodium metabisulfite (0.1mL) was added. After warming up to room temperature, the mixture was directly purified by chromatography (hexane-ethyl acetate 1-2) to afford the title compound (0.009g, 0.017mmol) as an oil.

MS (ESI,  $m/z$ ): 510.5 [ $M+H^+$ ]

$^1H$  NMR (300MHz,  $CDCl_3$ ): 6.99 (s, 0.66H); 6.98 (s, 0.33H); 6.54 (s, 0.66H); 6.44 (s, 0.33H); 5.70 (td,  $J$ = 8.3, 10.7Hz, 0.66H); 5.6 (m, 0.33H); 5.48 (dd,  $J$ = 2.8, 9.3Hz, 0.66H); 5.4 (t,  $J$ = 4.9Hz, 0.33H); 5.20-5.11 (m, 1.33H); 5.53 (dd,  $J$ = 3, 8.7Hz, 0.33H); 4.34 (br d,  $J$ = 10.5Hz, 0.66H); 4.06 (d,  $J$ = 9.4Hz, 0.66H); 3.61 (m, 0.33H); 3.50 (m, 0.66H); 3.36 (q,  $J$ = 7.2Hz, 0.66H); 2.93 (m, 0.33H); 2.86-2.41 (m, H); 2.11 (s, 1.98H); 1.02 (s, 1.02H); 1.76 (s, 1.98H); 1.74 (s, 1.02H); 1.50 (d,  $J$ = 7.3Hz, 1.98H); 1.47 (s, 1.02H); 1.38 (d,  $J$ = 7.3Hz, 1.02H); 1.29 (s, 1.98H); 1.21 (s, 1.02H); 1.19 (s, 1.98H); 1.07-1.03 (two overlapped d, 3H).




(4*S*,7*R*,8*S*,9*S*,10*Z*,13*Z*,16*S*)-4,8-Dihydroxy-5,5,7,9,13-pentamethyl-16-[(*E*)-1-methyl-2-(2-methyl-1,3-thiazol-4-yl)-ethenyl]-6,6-dioxo-1-oxa-6 $\lambda^6$ -thia-cyclohexadeca-10,13-dien-2-one

To a solution of substrate (0.008g, 0.016mmol) in dichloromethane (0.5mL) was added at -78C, 3-chloroperoxybenzoic acid (0.0024 g, 0.012mmol). The reaction was stirred at the same temperature for 10 minutes and 10% sodium metabisulfite (0.1mL) was added. After warming up to room temperature, the mixture was directly purified by chromatography (hexane-ethyl acetate 1-4) to afford the title compound (0.0029g, 0.0055mmol) as an oil

MS (ESI, *m/z*) :526.3 [*M*+*H*<sup>+</sup>]

<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): 6.99 (s, 1H); 6.50 (s, 1H); 5.72 (m, 1H); 5.46-5.31 (m, 2H); 5.16 (m, 1H); 4.40 (m, 1H); 4.23 (m, 1H); 3.77 (q, *J*= 7.2Hz, 1H); 3.62 (d, *J*= 2.3Hz, 1H); 2.71 -2.54 (m, 4H); 2.73 (s, 3H); 2.48-2.38 (m, 2H); 2.30 (d, *J*= 3.6Hz, 1H); 2.11 (s, 3H); 1.73 (s, 3H); 1.50 (d, *J*= 7.2Hz, 3H); 1.43 (s, 3H); 1.37 (s, 3H); 1.08 (d, *J*= 6.6Hz, 3H).




(4R,7R,8S,9S,10Z,13Z,16S)-4,8-Dihydroxy-5,5,7,9,13-pentamethyl-16-[(E)-1-methyl-2-(2-methyl-1,3-thiazol-4-yl)-ethenyl]-6-oxo-1-oxa-6 $\lambda$ <sup>6</sup>-thia cyclohexadec-10,13-dien-2-one

To a solution of substrate (0.0103g, 0.021mmol) in dichloromethane (0.45mL) was added 3-chloroperoxybenzoic acid (0.004g, 0.022mmol). The mixture was stirred at -78C for 10 minutes and was diluted with ethyl acetate (0.45mL). The mixture was directly subjected to chromatography (hexane-ethyl acetate 1:4 then 0:1) to afford the title compound (0.0084g, 0.016mmol) as an oil

MS (ESI, m/z) :510.5 [M+H<sup>+</sup>]

<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): 6.96 (s, 1H); 6.48 (s, 1H); 5.74 (td, J= 7, 11.1Hz, 1H); 5.42 (t, J=10.3Hz, 1H); 5.28 (dd, J= 2.9, 8.3Hz, 1H); 5.18-5.12 (m, 2H); 4.84 (t, J= 7.2Hz, 1H); 4.22 (br d, J= 8.3Hz, 1H); 3.44 (q, J= 7.2Hz, 1H); 2.93 (dd, J= 7.9, 15.4Hz, 1H); 2.79 (dd, J= 6.3, 15.4Hz, 1H); 2.72 (s, 3H); 2.72-2.51 (m, 5H); 2.39 (m, 1H); 2.18 (s, 3H); 1.76 (s, 3H); 1.59 (s, 3H); 1.48 (d, J= 7.2Hz, 3H); 1.17 (d, J= 6.5Hz, 3H); 1.01 (s, 3H).



(4*R*,7*R*,8*S*,9*S*,10*Z*,13*Z*,16*S*)-4,8-Dihydroxy-5,5,7,9,13-pentamethyl-16-[(*E*)-1-methyl-2-(2-methyl-1,3-thiazol-4-yl)-ethenyl]-6,6-dioxo-1-oxa-6λ<sup>6</sup>-thia-cyclohexadeca-10,13-dien-2-one


To a solution of substrate (0.008g, 0.016mmol) in dichloromethane (0.5mL) was added at -78°C, 3-chloroperoxybenzoic acid (0.0024 g, 0.012mmol). The reaction was stirred at the same temperature for 10 minutes and 10% sodium metabisulfite (0.1mL) was added. After warming up to room temperature, the mixture was directly purified by chromatography (hexane-ethyl acetate 1-4) to afford the title compound (0.0029g, 0.0055mmol) as an oil

MS (ESI, *m/z*) :526.3 [M+H<sup>+</sup>]

<sup>1</sup>H NMR (300MHz, CDCl<sub>3</sub>): 6.98 (s, 1H); 6.54 (s, 1H); 5.73 (td, *J*= 9.0, 9.6Hz, 1H); 5.52 (dd, *J*= 2.6, 9.6Hz, 1H); 5.34 (t, *J*= 10.6Hz, 1H); 5.10 (dd, *J*= 5.1, 10.2Hz, 1H); 4.42 (d, *J*= 8.7Hz, 1H); 4.13 (dd, *J*= 3.5, 10.2Hz, 1H); 3.67 (q, *J*= 6.8Hz, 1H); 3.41 (br s, 1H); 3.00 (dd, *J*= 10.6, 16.7Hz, 1H); 2.82-2.56 (m, 5H), 2.72 (s, 3H); 2.33 (m, 1H); 2.11 (s, 3H); 2.08 (br s, 1H); 1.70 (s, 3H); 1.56 (s, 3H); 1.50 (d, *J*= 6.9Hz, 3H); 1.36 (s, 3H); 1.11 (d, *J*= 6.5Hz, 3H).


The corresponding epoxides of all 5-thioepothilone derivatives are obtained by known procedures (Nicolaou et al. Angew. Chem. Int. Ed. 1998, 37, 2014-2045)

An alternative approach to synthesize the compounds of the present invention herein follows the route described in WO0232844. In these schemes, the groups P<sup>1</sup>, P<sup>2</sup> and P<sup>3</sup> independently represent hydrogen or protecting groups, such as Acetyl or TBDMS)






56



## Claims

## 1. Compounds of Formula (I)



wherein

A is a heteroalkyl-, heterocycloalkyl-, heteroalkylcycloalkyl-, heteroaryl- or heteroarylalkyl-group,

U is hydrogen, halogen, an alkyl, heteroalkyl-, heterocycloalkyl-, heteroalkylcycloalkyl-, heteroaryl- or heteroarylalkyl-group,

G-E is selected from the following groups,



or is part of an optionally substituted phenyl ring,

R<sup>1</sup> is a C<sub>1</sub>-C<sub>4</sub>-alkyl-, a C<sub>2</sub>-C<sub>4</sub>-alkenyl-, a C<sub>2</sub>-C<sub>4</sub>-alkinyl- or a C<sub>3</sub>-C<sub>4</sub>-cycloalkyl-group,

V-W is a group of formula CH<sub>2</sub>CH or CH=C,



X is oxygen or a group of the formula NR<sup>2</sup>, wherein R<sup>2</sup> is hydrogen, an alkyl-, alkenyl-, alkynyl-, heteroalkyl-, aryl-, heteroaryl-, cycloalkyl-, alkylcycloalkyl-, hetero-

alkylcycloalkyl-, heterocycloalkyl-, aralkyl- or hetero-arylalkyl-group and

$R^3$  and  $R^4$  independently from each other represent hydrogen,  $C_1$ - $C_4$ -alkyl or together are part of a cycloalkyl group with 3 or 4 ring atoms,

or a pharmacologically acceptable salt, solvate, hydrate or formulation thereof.


2. Compounds according to claim 1, wherein A is a group of the formula  $-C(CH_3)=CHR^5$  or  $-CH=CHR^5$ , wherein  $R^5$  is a heteroaryl- or a heteroarylalkyl group.
3. Compounds according to claim 1, wherein A is a group of formula (II) or (III)



wherein Q is sulphur, oxygen or  $NR^7$ , wherein  $R^7$  is hydrogen,  $C_1$ - $C_4$  alkyl or  $C_1$ - $C_4$  heteroalkyl, z is Nitrogen or CH and  $R^6$  is  $OR^8$ ,  $NHR^8$ ,  $C_1$ - $C_4$  alkyl,  $C_2$ - $C_4$  alkenyl,  $C_2$ - $C_4$  alkynyl or  $C_1$ - $C_6$  heteroalkyl, wherein  $R^8$  is hydrogen,  $C_1$ - $C_4$  alkyl or  $C_1$ - $C_4$  heteroalkyl.


4. Compounds according to any one of the preceding claims, wherein X is oxygen or NH.
5. Compounds according to any one of the preceding claims, wherein  $R^1$  is methyl or ethyl.

6. Compounds according to any one of the preceding claims, wherein  $R^3$  and  $R^4$  are methyl groups.
7. Compounds according to any one of the preceding claims, wherein U is hydrogen, fluorine, methyl, trifluoromethyl or COOH.
8. Compounds according to any one of the preceding claims, wherein G-E is selected from the following groups:



9. Compounds according to any one of the preceding claims, wherein V-W is  $\text{CH}_2\text{CH}$ .
10. Pharmaceutical compositions containing a compound, a pharmacologically acceptable salt, a solvate or a hydrate according to any one of the preceding claims or a prodrug of the compound, the salt, the solvate and/or the hydrate and optionally one or more carriers and/or one or more adjuvants and/or one or more diluents.
11. Use of a compound or a pharmaceutical composition according to any one of the preceding claims for the treatment of cancer
12. Use of a compound or a pharmaceutical composition according to any one of the preceding claims for the manufacture of a medicament for the treatment of cancer.

13. Compounds of formula (IVa), (IVb), (Va) and (Vb),



wherein the groups PG independently from each other represent hydrogen or protecting groups.

14. Use of a compound according to claim 13 for the synthesis of a compound of formula (I).

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 03/07664

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D417/06 C07D497/04 C07D417/04 C07D277/26 C07D327/06  
A61K31/426 A61P35/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	NICOLAOU, K C: "CHEMICAL BIOLOGY OF EPOTHILONES" ANGEWANDTE CHEMIE. INTERNATIONAL EDITION., vol. 37, August 1998 (1998-08), pages 2014-45, XP002131418 VERLAG CHEMIE. WEINHEIM., DE ISSN: 0570-0833 cited in the application page 2021 -page 2042 -----	1, 10-14

☐ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

### \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the international search

3 October 2003

Date of mailing of the international search report

14/10/2003

Name and mailing address of the ISA  
European Patent Office, P.B. 5618 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Francois, J